基于免疫微环境分析上尿路尿路上皮癌中成纤维细胞生长因子受体3的表达
本研究对214例上尿路尿路上皮癌(UTUC)患者行免疫组化染色,检测FGFR3、CD4、CD8、CD68、CD163、CD204及PD-L1表达。109例(50.9%)FGFR3高表达者预后较好。基于FGFR3的免疫聚类识别出三个免疫簇:A簇(FGFR3低表达伴CD204+肿瘤相关巨噬细胞富集)对帕博利珠单抗(Pem)反应差、预后不良;B簇(FGFR3低表达伴CD8+免疫热)对Pem反应好、预后最佳;C簇(FGFR3高表达伴免疫冷)预后好但对Pem反应差。作者认为FGFR3低表达且免疫热状态者可能从Pem治疗中临床获益。
要点
- 109例(50.9%)UTUC患者FGFR3高表达,预后较好。
- CD8高表达为独立有利因素,CD204表达为癌症死亡的独立预后因素。
- FGFR3低表达且免疫热状态者可能从帕博利珠单抗治疗中获益。
核心结论
- 虽然多数患者对帕博利珠单抗反应差,但FGFR3低表达且免疫热状态者可能从帕博利珠单抗治疗中获得临床获益。
研究设计与样本
- 对214例上尿路尿路上皮癌患者行免疫组化染色,检测FGFR3、CD4、CD8、CD68、CD163、CD204及PD-L1表达。
- 所有上尿路尿路上皮癌患者均行根治性肾输尿管切除术。
主要发现
- 109例(50.9%)患者FGFR3高表达,与其余患者相比预后较好。
- 六种免疫标志物中,CD8高表达为独立有利因素,CD204表达为癌症死亡的独立预后因素。
- 基于FGFR3的免疫聚类识别出三个免疫簇:A簇为FGFR3低表达伴肿瘤相关巨噬细胞富集成分(CD204+),对帕博利珠单抗反应差,预后不良。
- B簇为FGFR3低表达伴免疫热成分(CD8+),对帕博利珠单抗反应好,预后最佳。
- C簇为FGFR3高表达伴免疫冷成分,因FGFR3高表达预后较好,但对帕博利珠单抗反应差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although several studies have shown favorable outcomes in upper tract urothelial carcinoma (UTUC) with fibroblast growth factor receptor 3 (FGFR3) mutations and/or expression, the relationship between immune cell markers and FGFR3 expression remains unknown. OBJECTIVE: To clarify the FGFR3-based immune microenvironment and investigate biomarkers to predict the treatment response to pembrolizumab (Pem) in patients with UTUC. DESIGN, SETTING, AND PARTICIPANTS: We conducted immunohistochemical staining in 214 patients with UTUC. The expression levels of FGFR3, CD4, CD8, CD68, CD163, CD204, and programmed cell death ligand 1 (PD-L1) were examined. INTERVENTION: All UTUC patients underwent radical nephroureterectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the relationship between these immune markers and patient prognosis. RESULTS AND LIMITATIONS: A total of 109 (50.9%) patients showed high FGFR3 expressions and a favorable prognosis compared with the remaining patients. Among the six immune markers, CD8 high expression was an independent favorable factor, whereas CD204 expression was an independent prognostic factor for cancer death. From the FGFR3-based immune clustering, three immune clusters were identified. Cluster A showed low FGFR3 with tumor-associated macrophage-rich components (CD204+) followed by a poor prognosis due to a poor response to Pem. Cluster B showed low FGFR3 with an immune hot component (CD8+), followed by the most favorable prognosis owing to a good response to Pem. Cluster C showed high FGFR3 expression but an immune cold component, followed by a favorable prognosis due to the high FGFR3 expression, but a poor response was confirmed with Pem. CONCLUSIONS: Although most patients exhibit a poor response to Pem, individuals with low FGFR3 expression and immune hot status may benefit clinically from Pem treatment. PATIENT SUMMARY: We conducted immunohistochemical staining to evaluate fibroblast growth factor receptor 3 (FGFR3)-related immune microenvironment by evaluating the expressions of CD4, CD8, CD68, CD163, CD204, and PD-L1 in 214 upper tract urothelial carcinoma patients. We identified three distinct immune clusters based on FGFR3 expressions and found that patients with a low FGFR3 expression but immune hot status received the maximum benefit from an immune checkpoint inhibitor.
引用
- Shigeta K, Matsumoto K, Kitaoka S, et al. Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2024. PMID: 38320909. doi:10.1016/j.euo.2024.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。